Additionally, directly suppressing XBP1 in melanoma cells enhances the effectiveness of immunotherapy when treated with antibodies targeting proteins involved in the programmed cell death 1 (PD‐1) and cytotoxic T cell lymphocyte‐associated antigen 4 (CTLA‐4) pathways [92]. The gene discussed is XBP1; the disease is melanoma.